CD81 通过阻断 CD274/PD-L1 的选择性自噬降解驱动放射抵抗性胶质母细胞瘤的免疫逃逸
CD81 drives immune evasion in radioresistant glioblastoma by blocking selective autophagic degradation of CD274/PD-L1.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
间充质干细胞来源外泌体在抗肿瘤药物靶向递送中的进展
英文原题：Progress of mesenchymal stem cell-derived exosomes in targeted delivery of antitumor drugs.
查看英文原题
Progress of mesenchymal stem cell-derived exosomes in targeted delivery of antitumor drugs.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
间充质干细胞（MSC）目前正在多种疾病的临床试验中使用，在组织工程和再生领域应用广泛。外泌体是含有蛋白质、核酸和脂质等多种成分的细胞外囊泡，广泛存在于生物体液中，可参与细胞间信息传递、免疫应答和组织修复；还可作为载体靶向并递送肿瘤治疗药物，提高治疗效果。间充质干细胞来源外泌体（MSC-Exo）免疫原性低、肿瘤归巢能力强，因此在靶向药物递送领域受到广泛关注。本文回顾MSC-Exo参与肿瘤进展的现有认识及其作为靶向治疗药物递送系统的潜力，并讨论MSC-Exo作为药物载体的优势、前景及仍需克服的挑战。
展开英文摘要原文
Mesenchymal stem cells (MSCs) are currently being used in clinical trials for the treatment of a wide range of diseases and have a wide range of applications in the fields of tissue engineering and regeneration.
Exosomes are extracellular vesicles containing a variety of components such as proteins, nucleic acids and lipids, which are widely present in biological fluids and have the functions of participating in intercellular information transfer, immune response and tissue repair, and can also be used as carriers to target and deliver tumors to improve therapeutic effects. Mesenchymal stem cell-derived Exosomes (MSC-Exos), which have the advantages of low immunogenicity and high tumor homing ability, have attracted much attention in targeted drug delivery.
Here, we review the current knowledge on the involvement of MSC-Exos in tumor progression and their potential as drug delivery systems in targeted therapies. It also discusses the advantages and prospects of MSC-Exos as a drug carrier and the challenges that still need to be overcome.
论文信息
- 作者
- Huang D、Huang W、Liu M、Chen J、Xiao D、Peng Z、He H、Shen H
- 第一作者单位
- Laboratory Medicine, First Affiliated Hospital of Gannan Medical University, Ganzhou, 341000, China.China
- 通讯作者单位
- Laboratory Medicine, First Affiliated Hospital of Gannan Medical University, Ganzhou, 341000, China. 13879789666@163.com.China
- 文献类型
- 综述
- 期刊
- Cancer cell international2025 Apr 29
- 原文标识
- PubMed 40301903 · DOI 10.1186/s12935-025-03795-x
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →